
    
      Eligibility Criteria:

        -  18 -70 years old;

        -  Patients with measurable, histologically proven, inoperable HCC;

        -  Child-Pugh (CP) score of A;

        -  Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.

        -  Patients received prior systemic treatments for HCC before 4 weeks;

        -  Patients received operate before 3 months;

        -  Patients received TACE before 4 weeks;

        -  Life expectancy at least 3 months;

        -  Adequate hepatic and renal function;

        -  Adequate hematologic function (platelet count,≥70×109per liter;hemoglobin ≥8.5 g per
           deciliter);

        -  Prothrombin time international normalized ratio≤2; or prothrombin time ≤16 seconds;or
           APTT≤43s;or TT≤21s.

      Exclusion Criteria:

        -  Patients had prior treatment with sorafenib;

        -  CNS involvement.

      Method:

        -  open-label,randomized,multiceters study;

        -  2 dose cohorts: 200mg bid and 300mg bid;

        -  Patients with advanced HCC(inoperable) and Child-Pugh (CP) A , randomized,receive
           continuous donafenib either 200mg bid or 300mg bid in 4 weeks cycles;

        -  Sample size:106 patients(53 patients in each dose cohort).

      Endpoints:

        -  Safety: toxicities are assessed according to CTCAE 3.0;

        -  TTP:Tumor response is assessed every two cycles using RECISIT1.1 criteria;

        -  Donafenib pharmacokinetics is measured in plasma samples.
    
  